Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVC-110
- Development stage
- Preclinical
- Lead developer
- BioVinc
- Modality
- Small Molecules
- Administration
- Implant, Intraperitoneal, Intravenous, Oral
01
Overview
BVC-110 (also known as BV63072 or OsteoFloxacin) is a preclinical-stage, bone-targeted small molecule antibiotic conjugate developed by BioVinc for the treatment of chronic musculoskeletal infections, including osteomyelitis, prosthetic joint infections (PJI), and implant-associated bone infections. Chemically, BVC-110 is a hydroxybisphosphonate-conjugated sitafloxacin (HBCS). It utilizes a 'target-and-release' mechanism of action: the hydroxybisphosphonate moiety binds with high affinity to hydroxyapatite (bone mineral) at sites of active bone remodeling or infection, localizing the drug within the osteocyte lacunar-canalicular network (OLCN). Upon binding, the sitafloxacin payload is released to exert its potent, dual-targeting bactericidal activity against bacterial DNA gyrase and topoisomerase IV, effectively eradicating mature biofilms, including those formed by methicillin-resistant *Staphylococcus aureus* (MRSA).
- Brand names
- OsteoFloxacin
- Other names
- HBCSOsteoFloxacin Conjugatebisphosphonate-conjugated sitafloxacinhydroxybisphosphonate-conjugated sitafloxacin
02
Targets
DNADNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on BVC-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVC-110.